Archie Goodburn, a 24-year-old British swimmer facing a rare and inoperable form of brain cancer, is making an impassioned plea for the UK government to increase its support for individuals battling this devastating illness. After recently benefiting from a breakthrough treatment, Goodburn is determined to raise awareness about the urgent need for more effective research and funding in the field of brain cancer.
A Life-Changing Diagnosis
Goodburn’s journey took a dramatic turn two years ago, just as he was preparing to qualify for the Paris Olympics. He began experiencing unsettling symptoms during his training sessions, including loss of strength, numbness on his left side, and overwhelming feelings of fear and nausea. “I felt like my consciousness was being pulled away from me,” he recalled.
In April 2024, Goodburn narrowly missed out on qualifying, and subsequent medical examinations revealed he had three oligodendrogliomas—rare brain tumours that account for only 3% of all brain cancer cases.
A Glimmer of Hope
Fortunately, Goodburn’s situation took a positive turn when he was treated with Vorasidenib, a revolutionary medication that has allowed him to return to competitive swimming. This treatment has postponed the need for chemotherapy and radiotherapy, which could have severely impacted his cognitive abilities and interfered with his studies in chemical engineering.
However, Goodburn insists that one new drug in two decades is insufficient. “Vorasidenib only bought me four years, according to the trials. I need more. And I’m not going to stop campaigning until my last breath,” he asserted. His commitment to advocacy stems from the stark realities surrounding funding and research for brain cancer treatments.
A Call for Action
Brain cancer remains the leading cause of cancer-related deaths among children and adults under 40, yet it has received a mere 1% of the UK government’s national cancer research budget since 2002. Progress in drug development has been painfully slow, and Goodburn highlights the “translational gap” that exists between promising early-phase research and clinical trials accessible to patients.
The all-party parliamentary group on brain tumours has identified this gap as the “valley of death,” attributing it to a risk-averse funding model that hampers progress in a notoriously complex disease. Even when funds are allocated, regulatory hurdles often obstruct their utilisation. For instance, a fraction of the £40 million pledged by the government for brain cancer in 2018 has been used in subsequent years.
Goodburn, along with the Brain Cancer Justice campaign, is urging the government to release the remaining £40 million and ensure it directly supports frontline researchers. They are also advocating for the appointment of a dedicated brain cancer lead within the government, increased genome sequencing for newly diagnosed patients, and a “right to try” policy for potentially life-saving treatments.
Government Response
In light of the ongoing advocacy, the Department of Health and Social Care has acknowledged the need for enhanced research into brain tumours, stating they are committed to improving patient access to innovative treatments.
Goodburn’s standard treatment regimen, which typically involves radiotherapy and chemotherapy, was set to commence last July had he not been granted access to Vorasidenib through an expanded access programme. The medication works by halting the production of proteins vital for the growth of his tumours.
Following his treatment, Goodburn achieved a remarkable feat by breaking the Scottish record in the 50m breaststroke, the event he is set to compete in at the upcoming Commonwealth Games in Glasgow. His accomplishments serve as a testament to the transformative potential of new treatments, enabling individuals to pursue their passions despite daunting diagnoses.
The Balancing Act of Advocacy and Competition
As he prepares for the Commonwealth Games, Goodburn faces the additional challenge of advocating for brain cancer research while maintaining his training regimen. “I campaign because of the disparity in care, the lack of funding, but also because I believe that my campaigning can actually make a difference to my own future,” he remarked. “In some ways, it’s a treatment of its own.”
His journey exemplifies the intersection of personal struggle and broader systemic issues, highlighting the urgent need for change in the landscape of brain cancer research and treatment.
Why it Matters
Goodburn’s courageous advocacy sheds light on the pressing need for increased funding and support for brain cancer research in the UK. With brain cancer being a leading cause of cancer-related mortality among young people, it is crucial for the government and society as a whole to respond to the calls for action. His story not only raises awareness about the challenges faced by those with rare forms of cancer but also illustrates the profound impact that robust research funding and policy changes can have on the lives of patients. The time for action is now; lives depend on it.
